Ramorelix
| Code | Size | Price |
|---|
| TAR-T26040-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Ramorelix is an antagonist of luteinizing hormone-releasing hormone (LHRH).
CAS:
127932-90-5
Formula:
C74H95ClN16O18
Molecular Weight:
1532.12
Purity:
0.98
SMILES:
CC(C)C[C@H](NC(=O)[C@@H](CO[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
References
1. Stoeckemann K, Sandow J. Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations. J Cancer Res Clin Oncol. 1993;119(8):457-62. PubMed PMID: 8509436.
2. Ermer J. The use of hyphenated LC-MS technique for characterisation of impurity profiles during drug development. J Pharm Biomed Anal. 1998 Dec;18(4-5):707-14. PubMed PMID: 9919972.